Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Medtronic
Harvard Business School
Baxter
AstraZeneca

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 10,130,632

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,130,632
Title:Methods for treating renal disease
Abstract: The invention features methods for treating or reducing the likelihood of developing a renal disease by administering to a subject in need thereof an agent that decreases expression of a pathogenic APOL1. The agents of the method target various signaling pathways and decrease the level of the pathogenic APOL1 polypeptide.
Inventor(s): Friedman; David J. (Boston, MA), Pollak; Martin R. (Boston, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Application Number:14/646,055
Patent Claims:see list of patent claims

Details for Patent 10,130,632

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2017-05-26   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) 2039-02-26 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) 2039-02-26 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) 2039-02-26 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) 2039-02-26 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Moodys
McKesson
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.